Catalyst Pharmaceuticals, Inc. Common Stock, also called Catalyst Pharmaceuticals, is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasmsThe company was founded Huckel E. Read More Hubert in January 2002 and is headquartered in Coral Gables, FL.